Immuneering Corp

IMRX

Company Profile

  • Business description

    Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

  • Contact

    245 Main Street
    Second Floor
    CambridgeMA02142
    USA

    T: +1 617 500-8080

    https://www.immuneering.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    66

Stocks News & Analysis

stocks

16 ASX stocks to buy and hold forever, revisited

This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now. 
stocks

This ASX200 reject could be a contrarian buying opportunity

Johns Lyng’s interim results and index deletion have sent investors running for the exits. Our analyst Esther Holloway thinks the sell-off is overdone. 
stocks

A 15 step checklist from Buffett's forgotten inspiration

Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,002.60100.80-1.24%
CAC 407,988.9647.050.59%
DAX 4022,676.41347.641.56%
Dow JONES (US)41,449.0115.530.04%
FTSE 1008,540.9744.980.53%
HKSE23,600.31181.83-0.76%
NASDAQ17,657.20221.111.27%
Nikkei 22536,819.0925.980.07%
NZX 50 Index12,249.55161.42-1.30%
S&P 5005,609.6137.540.67%
S&P/ASX 2007,786.20103.90-1.32%
SSE Composite Index3,371.927.90-0.23%

Market Movers